Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA approves IV Nexium for GERD in babies

This article was originally published in Scrip

Executive Summary

The US FDA approved AstraZeneca's intravenous form of Nexium (esomeprazole sodium) for children as young as 1 month for the short-term treatment of gastroesophageal reflux disease (GERD) with erosive esophagitis, or inflammation of the esophagus, when oral therapy is not possible or appropriate – making it the first proton-pump inhibitor approved for children under 12 months.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel